-
Secondary analysis of pain outcomes in a large pragmatic randomized trial of buprenorphine/naloxone versus methadone for opioid use disorder.
Shulman M, Luo S, Campbell ANC, Scodes J, Pavlicova M, Broffman A, Saxon AJ, Nunes EV. Secondary analysis of pain outcomes in a large pragmatic randomized trial of buprenorphine/naloxone versus methadone for opioid use disorder. Journal of Addiction Medicine 2020;14(5):e188-e194.
-
The application of digital health to the assessment and treatment of substance use disorders: The past, current, and future role of the National Drug Abuse Treatment Clinical Trials Network.
Marsch LA, Campbell ANC, Campbell C, Chen C, Ertin E, Ghitza U, Lambert-Harris C, Hassanpour S, Holtyn AF, Hser Y, Jacobs P, Klausner JD, Lemley S, Kotz D, Meier A, McLeman B, McNeely J, Mishra V, Mooney L, Nunes EV, Stafylis C, Stanger C, Saunders E, Subramaniam G, Young S. The application of digital health to the assessment and treatment of substance use disorders: The past, current, and future role of the National Drug Abuse Treatment Clinical Trials Network. Journal of Substance Abuse Treatment 2020;112S:4-11
-
Comparison of timeline follow-back self-report and oral fluid testing to detect substance use in adult primary care patients.
Nordeck CD, Gryczynski J, O'Grady KE, Polak K, Svikis DS, McNeely J, Wu L, Schwartz RP. Comparison of timeline follow-back self-report and oral fluid testing to detect substance use in adult primary care patients. Drug and Alcohol Dependence 2020;209:107939.
-
The National Drug Abuse Treatment Clinical Trials Network: From 2000 to 2020 and beyond. [editorial]
McCarty D, Donovan DM. The National Drug Abuse Treatment Clinical Trials Network: From 2000 to 2020 and beyond. [editorial] Journal of Substance Abuse Treatment 2020;112S:1-3.
-
Treatment trajectories during and after a medication trial for opioid use disorder: Moving from research as usual to treatment as usual.
Fishman MJ, Voa HT, Burgower R, Ruggiero M, Rotrosen J, Lee J, Nunes EV. Treatment trajectories during and after a medication trial for opioid use disorder: Moving from research as usual to treatment as usual. Journal of Addiction Medicine 2020;14(4):331-336.
-
Parallel modeling of pain and depression in prediction of relapse during buprenorphine and naloxone treatment: A finite mixture model.
Vest NA, McPherson S, Burns GL, Tragesser S. Parallel modeling of pain and depression in prediction of relapse during buprenorphine and naloxone treatment: A finite mixture model. Drug and Alcohol Dependence 2020;209:107940
-
Predictors of HIV sex risk behavior among women in us drug treatment programs: NIDA CTN trial results.
Spector AY, Pavlicova M, Hu M, Nunes EV, Campbell ANC, Tross S. Predictors of HIV Sex Risk Behavior Among Women in US Drug Treatment Programs: NIDA CTN Trial Results. Journal of HIV/AIDS & Social Services 2020;19(1):90-106.
-
Psychosocial intervention utilization and substance abuse treatment outcomes in a multisite sample of individuals who use opioids.
Harvey L, Fan W, Cano MA, Vaughan E, Arbona C, Essa S, Sanchez H, de Dios MA. Psychosocial intervention utilization and substance abuse treatment outcomes in a multisite sample of individuals who use opioids. Journal of Substance Abuse Treatment 2020;112:68-75.
-
Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
Lapham G, Boudreau DM, Johnson EA, Bobb JF, Matthews AG, McCormack J, Liu D, Samet JH, Saxon AJ, Campbell CI, Glass JE, Rossom RC, Murphy MT, Binswanger IA, Yarborough BJH, Bradley KA. Prevalence and treatment of opioid use disorders among primary care patients in six health systems. Drug and Alcohol Dependence 2020;207:107732
-
The association between regular cannabis use, with and without tobacco co-use, and adverse cardiovascular outcomes: Cannabis may have a greater impact in non-tobacco smokers.
Winhusen TJ, Theobald J, Kaelber DC, Lewis D. The association between regular cannabis use, with and without tobacco co-use, and adverse cardiovascular outcomes: Cannabis may have a greater impact in non-tobacco smokers. American Journal of Drug and Alcohol Abuse 2020;46(4):454-461